Lista de obras - Eduardo Vilar Gómez - Dominio Público Uruguay

ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis

scientific article published on 25 September 2020

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.

artículo científico publicado en 2009

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

artículo científico publicado en 2018

Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug

artículo científico publicado en 2019

Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.

artículo científico publicado en 2016

Editorial: treating the liver to treat the kidney in non-alcoholic steatohepatitis - authors' reply.

artículo científico publicado en 2017

Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]

scientific article published on 01 August 2018

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

artículo científico publicado en 2018

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease

artículo científico publicado en 2016

Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis.

artículo científico publicado en 2015

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.

artículo científico publicado en 2016

Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply

artículo científico publicado en 2019

Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply

artículo científico publicado en 2019

Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

scientific article published on 03 June 2019

Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?

scientific article published on 21 June 2016

Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden

artículo científico publicado en 2018

Reply

artículo científico publicado en 2016

Reply

Reply to Letter to the Editor HEP-20-2462 and HEP-20-2655

artículo científico publicado en 2020

Reply: To PMID 25865049.

artículo científico publicado en 2015

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.

artículo científico publicado en 2017

The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

scientific article published on 23 October 2018

Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis

scientific article published on 06 March 2019

Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

artículo científico publicado en 2007

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

artículo científico publicado en 2015

[Sequential combination therapy with prednisone, lamivudine and interferon alfa-2b for HBeAg-positive chronic hepatitis B]

artículo científico publicado en 2006

Lista de obras de Eduardo Vilar Gómez

ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug

Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.

Editorial: treating the liver to treat the kidney in non-alcoholic steatohepatitis - authors' reply.

Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease

Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis.

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.

Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply

Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply

Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?

Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden

Reply

Reply

Reply to Letter to the Editor HEP-20-2462 and HEP-20-2655

Reply: To PMID 25865049.

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.

The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis

Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

[Sequential combination therapy with prednisone, lamivudine and interferon alfa-2b for HBeAg-positive chronic hepatitis B]